Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 75/18.75/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 100/25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 125/31.25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 150/37.5/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 175/43.75/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 200/50/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

schwarz pharma - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - tablet, orally disintegrating - 25 mg - parcopa®   is indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. parcopa®   is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. however, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. although the administration of carbidopa permits control of parkinsonism and parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing naus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodo

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

mayne pharma inc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets usp are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administe

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodo